Brain and Nervous System

23 protocols meet the specified criteria
Disease Site: Brain and Nervous System
Protocol No. Title
OCR13165 Dendritic Cell (DC) and Tumor-Specific Cytotoxic T Cell (CTL) Generation Protocol from Healthy Volunteers and Patients with Malignant Brain Tumors
OCR13166 Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
OCR13631 Molecular Analysis for Therapy Choice (MATCH)
OCR14009 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
OCR14089 Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
OCR14127 A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Patients with Newly-Diagnosed Glioblastoma
OCR14627 A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas
OCR14652 A Phase 2/3 Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
OCR14655 A Phase II Study of the Optune System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma Multiforme
OCR14673 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial
OCR14874 A Phase 2, Multi-center, Single arm, Histologically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients with Bevacizumab-refractory Recurrent Glioblastoma
OCR14958 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
OCR14992 Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
OCR15092 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
OCR15132 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
OCR15154 A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
OCR15240 Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
OCR15952 Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
OCR15982 A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults with Recurrent or Progressive Primary Brain Tumors
OCR16016 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
OCR16397 Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy Adjuvant Temozolomide Plus Optune Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma (2-THE-TOP)
OCR16897 ACNS1422, A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
OCR16937 A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors